Pires Ana Carolina, Uson Junior Pedro Luiz Serrano
Department of Oncology, Oncoclínicas, Rio de Janeiro 22250905, Brazil.
Hospital Universitário Gaffrée e Guinle, Rio de Janeiro 22250905, Brazil.
World J Gastrointest Oncol. 2025 Jul 15;17(7):104806. doi: 10.4251/wjgo.v17.i7.104806.
This article provides a critical analysis of a prospective single arm study by Zheng , which assessed the impact of oxaliplatin and trastuzumab, administered every 3 weeks, for a total of six cycles in 60 patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. The study specifically explored how this treatment regimen influenced serum tumor markers and T lymphocyte subsets. After six cycles of treatment, the levels of the tumor markers carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 72-4 in the blood significantly dropped compared to their initial values ( < 0.001). There was a notable increase in the percentages of CD3+ and CD4+ T cells ( < 0.05), while the percentage of CD8+ T cells decreased ( < 0.05). As a result, the CD4+/CD8+ ratio also rose significantly after treatment ( < 0.05). Patients who had a reduction of 50% or more in their tumor markers and an increase of 1.5 times or more in the CD4+/CD8+ ratio showed better clinical improvements ( < 0.05). In this editorial, we will discuss these findings and how they apply to the current treatment field for advanced HER2 positive gastric cancer.
本文对郑的一项前瞻性单臂研究进行了批判性分析，该研究评估了每3周给药一次的奥沙利铂和曲妥珠单抗对60例人表皮生长因子受体2（HER2）阳性晚期胃癌患者总共六个周期的影响。该研究特别探讨了这种治疗方案如何影响血清肿瘤标志物和T淋巴细胞亚群。六个周期的治疗后，血液中的肿瘤标志物癌胚抗原、糖类抗原19-9和糖类抗原72-4水平与初始值相比显著下降（<0.001）。CD3+和CD4+T细胞百分比显著增加（<0.05），而CD8+T细胞百分比下降（<0.05）。因此，治疗后CD4+/CD8+比值也显著升高（<0.05）。肿瘤标志物降低50%或更多且CD4+/CD8+比值增加1.5倍或更多的患者显示出更好的临床改善（<0.05）。在这篇社论中，我们将讨论这些发现以及它们如何应用于当前晚期HER2阳性胃癌的治疗领域。
